For example, a Phase I trial recently investigating a combination treatment with aromatase inhibitor exemestane and a carboplatin-based therapy for postmenopausal women with advanced NSCLC showed a significant correlation between overall response rate with level of positive aromatase IHC expression (52). Here, CYP19A1 is linked to non-small cell lung carcinoma.